Cambrian Biopharma

Start Date

End Date Funded Value Relevance

CSV

25 50 100

£1,847,259

Jan 20 - Nov 22

MICA: Novel inhibitors of Transglutaminase 2 (TG2), a new therapy to halt the progression of diabetic cardiomyopathy

MRC award to Aston University and Martin Griffin

{{facetGroup.name}}

{{getFilterText(facet,showCount)}}